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Multidrug resistance associated protein 3 (ABCC3/MRP3) mediates the efflux of bile salts
and several conjugated organic anions out of cells and could be involved in protecting tis-
sues from xenobiotic accumulation and resulting toxicity. In this report, we investigated
the hypothesis that a functional missense variant, namely the Arg1297His, and a polymor-
phism in the promoter region, namely the –211 C > Tof the ABCC3 gene, could be associated
with colorectal cancer risk. We did not find any significant association between the two
ABCC3 polymorphisms and colorectal cancer risk.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
Transporters are the gatekeepers for all cells and organelles,
controlling uptake and efflux of crucial compounds such as
sugars, amino acids, nucleotides, inorganic ions and drugs.
It is generally assumed that at least 5% (>2000) of all human
genes are transporter-related.1
Amongst the most important active transporters, ATP-
binding cassette C3/multidrug resistance associated protein
3 (ABCC3/MRP3) is a relatively well-studied member of the
ABC transporter family. It has a restricted tissue distribution
pattern, being expressed in liver, pancreas, small intestineer Ltd. All rights reserved
; fax: +49 6221 421810.
zian).and colon, with lower amounts of mRNA detected in bladder,
kidney, pancreas, lung, spleen, stomach and tonsils.2–4 In
polarised epithelial cells, ABCC3/MRP3 localises to the basolat-
eral membrane. It mediates the efflux of bile salts and several
conjugated organic anions out of cells.5–9 ABCC3/MRP3 role in
drug resistance is well-known to be one of the most important
amongst ABCs.10,11 In addition, ABCC3/MRP3 is expressed in
many non-malignant tissues, including the colon, and could
be involved in protecting tissues from xenobiotic accumula-
tion and resulting toxicity.12 ABCC3/MRP3-mediated export of
conjugates of endogenous substances, such as bilirubin glu-
coronosides, and xenobiotic substances, such as anti-cancer.
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various epithelial cell types. Zimmerman and coworkers, in a
report exploring the expression of ABCs in the human gut,13
showed that the ABCC3 gene is, in large part of the intestine,
one of the most expressed transporters of this family. This
indicates that mutations in ABCC3 may critically affect
MRP3-mediated pathways of detoxification in human colon,
and could thus have a role in cancer susceptibility.
In this report, we investigated the hypothesis that a func-
tional missense variant, namely the Arg1297His, and a poly-
morphism in the promoter region, namely the –211 C > T of
the ABCC3 gene could be associated with colorectal cancer
risk (CRC). We performed a case–control study based on 680
cases and 590 controls from the Czech population. We
focused our attention on these two SNPs because of their rel-
ative high frequency in the Caucasian population and because
amino acid Arg1297 is located close to the second nucleotide
binding domain (NBD) and therefore may cause deficient mat-
uration and impaired trafficking of the protein. The polymor-
phism located in the promoter region is associated with the
expression of the gene, as recently reported by Lang.14 More-
over, this is the most comprehensive study on the ABCC3 gene
polymorphisms which may be relevant pharmacogenetically.
2. Materials and methods
2.1. Study population
A hospital-based case–control study was conducted to study
CRC risk. Cases were CRC patients attending nine oncological
departments (two in Prague, one each in Benesov, Brno, Lib-
erec, Ples, Pribram, Usti nad Labem and Zlin) distributed in
all geographic regions of Czech Republic and covering over
half of the population of the country. During the study period
(September 2004 to February 2006), a total of 968 cases were
diagnosed with CRC in these hospitals. This study includes
680 (70%) patients who could be interviewed and provided
biological samples of sufficient quality for genetic analysis.
The lost cases were similar to those enrolled with respect to
age, sex, tumour location and extent. All cases had histologi-
cal confirmation of their tumour diagnosis. In the group of
cases the genetic testing for hereditary HNPCC was recom-
mended to 4 patients, who belonged to families complying
with the Amsterdam criteria II. These patients were excluded
from our study.
Controls were selected amongst patients admitted to five
large gastroenterological departments (Prague, Brno, Jihlava,
Liberec and Pribram) all over the Czech Republic, during the
same period of the recruitment of cases. Controls were sub-
jects undergoing colonoscopy for various gastrointestinal
complaints. The reasons to proceed to colonoscopy for both
cases and controls were (i) macroscopic bleeding; (ii) positive
fecal occult blood test (FOBT); (iii) abdominal pain of un-
known origin. Due to the high incidence of CRC in the Czech
Republic, colonoscopy is largely recommended and practiced,
and it is compulsory in case of a positive FOBT. The most
common findings for these subjects were haemorrhoids or
idiopatic bowel diseases (IBD). Only subjects whose colono-
scopic results were negative for malignancy, colorectal adeno-
mas or IBD were chosen as controls. Amongst 739 invitedcontrols, a total of 590 (79.8%) were analysed in this study
(lost controls were similar to those included with respect to
sex distribution).
Cases included in this study had a median age of 62 years
(ranged 27–90), while controls had a median age of 56 years
(ranged 28–91). Men were slightly more frequent (57.2%
amongst cases and 53.6% of controls).
Study subjects provided information on their lifestyle hab-
its (smoking, drinking, diet, etc.), tentative occupational expo-
sure to xenobiotics and family/personal history of cancer,
with the use of structured questionnaires.15
Genetic analyses did not interfere with diagnostic or ther-
apeutic procedures for the subjects. All participants signed an
informed written consent and the design of the study was ap-
proved by the Ethical Committee of the Institute of Experi-
mental Medicine, Prague, Czech Republic.
2.2. DNA extraction and genotyping
DNA was isolated from coded blood samples with standard
proteinase K digestion, phenol/chloroform extraction and
ethanol precipitation, and stored at –80 C.
Genotyping was carried out using the Taqman assay (Ap-
plied Biosystems, Foster City, CA). The MGB Taqman probes
were designed using the Primer Express software and syn-
thesised by Applied Biosystems. The reaction mix included
20 ng genomic DNA, 10 pmol for each primer, 2 pmol for each
probe and 5 ll of 2· master mix (Applied Biosystems), in a fi-
nal volume of 10 ll. Thermocycling involved 40 cycles with
30 s at 95 C followed by 60 s at 60 C. PCR plates were read
on an ABI PRISM 7900HT instrument (Applied Biosystems).
Genotype discrimination was performed using SDS software
(Applied Biosystems), version 2.2. The PCR profile and reac-
tion conditions were tested and optimised in order to ensure
equal contents of template DNA, probes and primers and to
allow running with unique thermal conditions. All samples
that did not give a reliable result in the first round of genotyp-
ing were resubmitted for up to three additional rounds of
genotyping. Data points that still remained unfilled after this
procedure were left blank.
To ensure quality control, the order of DNA samples from
cases and controls was randomised on PCR plates to assure
that an equal number of cases and controls could be analysed
simultaneously, and all genotyping was conducted by person-
nel blinded to sample identity. Only genotype calls scored con-
cordantly by two independent trained operators were retained.
Finally, 8% of genotypes were repeated for quality control, and
yielded a concordance rate of 99.3%. Sequences of primers and
probes used for genotyping are available upon request.
2.3. Statistical analysis
The frequency distribution of genotypes was examined for
cases and controls. Hardy–Weinberg equilibrium was tested
in controls by Fisher’s exact test. We used logistic regression
for multivariate analyses to assess the main effects of the ge-
netic polymorphism on CRC risk. The primary end-points of
the analysis were odds ratios and associated confidence inter-
vals. All the analyses were done with STATA software (Stata-
Corp, College Station, TX).
Table 1 – Associations of ABCC3 functional polymorphisms with colorectal cancer risk
Casesa Controlsa,b OR (95%)c P value P trend
rs11568591 (Arg1297His)
A/A 590 548 1 0.74
A/G 67 43 1.44 (0.96–2.11) 0.07
G/G 1 1 0.92 (0.51–14.44) 0.64
A/G+G/G 68 44 1.43 (0.97–2.13) 0.07
rs4793665 (–211 C > T)
T/T 152 151 1 0.16
C/T 339 280 1.20 (0.91–1.58) 0.18
C/C 132 104 1.26 (0.89–1.77) 0.18
C/T + CC 471 384 1.22(0.94–1.58) 0.13
a Numbers may not add up to 100% of subjects due to genotyping failure. All samples that did not give a reliable result in the first round of
genotyping were resubmitted to up to three additional rounds of genotyping. Data points that were still not filled after this procedure were left
blank.
b Fisher’s exact test for deviation from Hardy–Weinberg equilibrium. P-values: 0.58 for rs11568591; 0.22 for rs4793665.
c OR: odds ratio; CI: confidence interval. Adjusted for age and gender.
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The genotype frequencies amongst the controls and cases
were in Hardy–Weinberg equilibrium for both SNPs. The fre-
quencies and distribution of the genotypes and the odds ratios
for the associations of the polymorphism are shown in Table 1.
We did not find any significant association between ABCC3 Ar-
g1297His or the –211 C > T polymorphisms and CRC risk, either
overall or when subjects were stratified on the basis of gender.
If such associations exist, they must be of a smaller magnitude
than what would be detectable with our study. Dividing the
cases in two groups by an arbitrary cut-off of 50 years at diag-
nosis, representing late onset versus early onset, we found
that individuals who exhibit a late onset and are homozygous
carriers for the C allele of the ABCC3 –211 C > T had an in-
creased risk of CRC (odds ratio 1.48, 95% confidence interval
1.00–2.21, p = 0.04). However, stratification by age using the
median age at onset (62-years-old) as cut-off did not show
any statistically significant difference.
We then divided the patients by the cancer site (colon ver-
sus rectum), and we did not find any association with the two
polymorphism and the different cancer sites. Moreover, there
was no interaction between the age at onset and the cancer
site (data not shown).
3.1. Statistical power
Our study has 80% power to detect a minimum odds ratio of 2
for the Arg1297His SNP, present with a minor allele frequency
(MAF) of 0.04 in our controls, and a minimum odds ratio of 1.4
for the –211 C > T (MAF = 0.46 in the controls of our study),
assuming a = 0.05, two-sided test and a codominant model.
4. Discussion
Human ABBC3/MRP3 is one of several ABC paralogs localised
to the basolateral membrane of polarised cells, and its
expression is constitutive in the intestine.12 Several amino
acid variations have been described that modulate the func-
tional properties of ABC transporters. Non-synonymousmutations in NBDs, which are highly conserved domains
amongst ABC transporters, may cause deficient maturation
and impaired trafficking.16 The Arg1297His SNP of ABCC3
has been postulated to exert such an effect.17 Lang and
coworkers14 showed that the –211 C > T polymorphism of
ABCC3 alters mRNA expression affecting the binding of nucle-
ar factors to the promoter. No other common polymorphisms
with established or putative functional relevance are known
in this gene.
The previously published functional data made these two
polymorphisms attractive candidates for affecting CRC risk.
In our case–control study, we did not find any statistically sig-
nificant association between either polymorphism and CRC
risk. Considering the low frequency of the Arg1297His SNP
and the available sample size in this study, we cannot exclude
that this polymorphism may be associated with a small alter-
ation of risk. Concerning the promoter polymorphism, we ob-
served a non-significant trend in the whole sample set and an
increased risk in the individuals with late onset of the dis-
ease, suggesting an interaction of the polymorphism and
age, although this was not observed when a different age
cut-off was used.
In conclusion, our study does not support a major role of
Arg1297His and –211 C > T polymorphisms of ABCC3 gene in
risk of CRC. In addition to the data on cancer risk, our study
provides information potentially relevant for pharmacogenet-
ics. Most drugs are developed based on data from European-
derived ‘reference’ populations, but clinically relevant DNA
polymorphisms often demonstrate population-specific pat-
terns of allele frequencies. The knowledge of the frequency
distribution of functional polymorphisms in a population
may guide national planning for the selection of therapeutic
options. Here, we present, to our knowledge, the largest exist-
ing study on two functional common polymorphisms in a key
gene such ABCC3, which is involved in determining the bio-
availability of many drugs.
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